Daniel B. Costa
Division of Hematology/Oncology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston
USA
Name/email consistency: high
- Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. Costa, D.B., Kobayashi, S. J. Thorac. Oncol (2012)
- Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Costa, D.B., Nguyen, K.S., Cho, B.C., Sequist, L.V., Jackman, D.M., Riely, G.J., Yeap, B.Y., Halmos, B., Kim, J.H., Jänne, P.A., Huberman, M.S., Pao, W., Tenen, D.G., Kobayashi, S. Clin. Cancer Res. (2008)
- A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. Costa, D.B., Fisher, C.A., Miller, K.B., Pihan, G.A., Steensma, D.P., Gibbons, R.J., Higgs, D.R. Eur. J. Haematol. (2006)